Skip to main content
ASND logo

ASND

Ascendis Pharma A/S

$274.50

2.51%

Trade Ideas Performance

Latest Closed Trade Idea

$274.50

2.51%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

8

Social

1

About

Events of Ascendis Pharma A/S (ASND)

Ascendis Pharma reported a net loss of €34 million for Q4 2025, and a full-year 2025 net loss of €228 million. The FDA granted accelerated approval to Ascendis Pharma's YUVIWEL for achondroplasia in children. Ascendis Pharma completed its transition to a direct listing of its ordinary shares on Nasdaq. The company reported a Q1 2026 EPS of €0.27, surpassing the forecast of €0.18, but revenue of €247 million fell short of the €269.95 million forecast. Ascendis Pharma decided to discontinue internal oncology development of TransCon IL-2 β/γ to focus on its endocrine pipeline and combination therapies.

Read more

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Ascendis Pharma A/S (ASND) Live Stock Price, Chart & Financial News | Edge Hound